143 related articles for article (PubMed ID: 35432745)
1. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy.
Conti CB; Mainardi E; Soro S; Testa S; De Silvestri A; Drago A; Cereatti F; Grassia R
World J Gastrointest Endosc; 2022 Mar; 14(3):153-162. PubMed ID: 35432745
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
[TBL] [Abstract][Full Text] [Related]
3. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease.
De Nicolò A; Cusato J; Bezzio C; Saibeni S; Vernero M; Disabato M; Caviglia GP; Ianniello A; Manca A; D'Avolio A; Ribaldone DG
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615826
[TBL] [Abstract][Full Text] [Related]
4. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
Berte' R; Mazza S; Stefanucci MR; Noviello D; Costa S; Ciafardini C; Mileti E; Mapelli M; Pasqualato S; Pinto S; Favale A; Vecchi M; Neurath MF; Atreya R; Fantini MC; Facciotti F; Caprioli F
J Crohns Colitis; 2021 May; 15(5):864-868. PubMed ID: 33211810
[TBL] [Abstract][Full Text] [Related]
6. Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.
Bosa L; Di Chiara C; Gaio P; Cosma C; Padoan A; Cozzani S; Perilongo G; Plebani M; Giaquinto C; Donà D; Cananzi M
Front Pediatr; 2022; 10():815857. PubMed ID: 35223697
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study.
Karłowicz K; Lewandowski K; Tulewicz-Marti E; Maciejewska K; Tworek A; Stępień-Wrochna B; Głuszek-Osuch M; Łodyga M; Rydzewska G
Prz Gastroenterol; 2024; 19(2):198-205. PubMed ID: 38939061
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F
Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.
Martin-Arranz MD; García-Ramírez L; Hernandez-Perez M; Montero Vega D; Martín-Arranz E; Sánchez-Azofra M; Poza Cordon J; Rueda Garcia JL; Noci Belda J; Verges Martínez-Meco T; Blanco San Miguel P; Suarez Ferrer C
Sci Rep; 2023 Apr; 13(1):7044. PubMed ID: 37120662
[TBL] [Abstract][Full Text] [Related]
10. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.
Di Ruscio M; Lunardi G; Buonfrate D; Gobbi F; Bertoli G; Piccoli D; Conti A; Geccherle A; Variola A
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684085
[No Abstract] [Full Text] [Related]
11. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.
Ardizzone S; Ferretti F; Monico MC; Carvalhas Gabrielli AM; Carmagnola S; Bezzio C; Saibeni S; Bosani M; Caprioli F; Mazza S; Casini V; Cortelezzi CC; Parravicini M; Cassinotti A; Cosimo P; Indriolo A; Di Sabatino A; Lenti MV; Pastorelli L; Conforti F; Ricci C; Sarzi-Puttini P; Vecchi M; Maconi G
J Gastroenterol Hepatol; 2021 Nov; 36(11):3050-3055. PubMed ID: 34159648
[TBL] [Abstract][Full Text] [Related]
12. Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Neri B; D'Agostini G; Salvatori S; Mossa M; Bettin F; Mancone R; Marafini I; Lolli E; Calabrese E; Monteleone G; Biancone L
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):948-954. PubMed ID: 37505974
[TBL] [Abstract][Full Text] [Related]
13. Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients.
Waggershauser CH; Tillack-Schreiber C; Weyh P; Alt E; Siegmund T; Berchthold-Benchieb C; Szokodi D; Schnitzler F; Ochsenkühn T
Can J Gastroenterol Hepatol; 2022; 2022():3469789. PubMed ID: 36060521
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel diseases and the clinical course of coronavirus disease 2019 - a Polish single-centre experience from the pre-vaccine era.
Banasik E; Dobrowolska A; Kołodziejczak B; Eder P
Prz Gastroenterol; 2023; 18(4):409-415. PubMed ID: 38572464
[TBL] [Abstract][Full Text] [Related]
15. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).
Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S
Gastroenterol Hepatol; 2024 Jan; ():. PubMed ID: 38219960
[TBL] [Abstract][Full Text] [Related]
16. [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease].
Teich N; Ludewig C; Schmelz R; Bästlein EC; Geißler S; Nagl S; Walldorf J; Krause T; Maaser C; Mohl W; Wedemeyer HH; Bauer T; Büning C; Grunert P; Hasselblatt P; Hänschen M; Kahl M; Engelke O; Schubert S; Holler B; Streetz K; Arnim UV; Schmidt K; Stallmach A; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Z Gastroenterol; 2021 Nov; 59(11):1189-1196. PubMed ID: 34748206
[TBL] [Abstract][Full Text] [Related]
17. Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?
Malickova K; Kratka Z; Luxova S; Bortlik M; Lukas M
Scand J Gastroenterol; 2020 Aug; 55(8):917-919. PubMed ID: 32663041
[TBL] [Abstract][Full Text] [Related]
18. PREVALENCE AND PREDICTIVE FACTORS ASSOCIATED WITH POSITIVITY OF SARS-COV-2 SEROLOGICAL MARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT AN IBD REFERRAL CENTER.
Ferreira SDC; Parra RS; Feitosa MR; Feres O; Santana RC; Troncon LEA
Arq Gastroenterol; 2022; 59(2):170-176. PubMed ID: 35830024
[TBL] [Abstract][Full Text] [Related]
19. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.
Siegel CA; Christensen B; Kornbluth A; Rosh JR; Kappelman MD; Ungaro RC; Johnson DF; Chapman S; Wohl DA; Mantzaris GJ
J Crohns Colitis; 2020 Oct; 14(14 Suppl 3):S769-S773. PubMed ID: 33085972
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 IgG antibody responses in rt-PCR-positive cases: first report from India.
Dash GC; Parai D; Choudhary HR; Peter A; Rout UK; Nanda RR; Kshatri JS; Kanungo S; Palo SK; Mandal N; Pati S; Bhattacharya D
Access Microbiol; 2021; 3(10):000267. PubMed ID: 34816087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
